SPK-8016

N/A

Report date: 2022/11/07 20:01:25

Base Information

Drug NameSPK-8016
Drug Alias Name第八因子基因疗法八因子基因疗法SPK-8016RG-6358
ClassificationBiologics
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor VIII modulatorsFactor VIII gene transference
TargetsCoagulation factor VIII
Therapy Area/IndicationsGenetic Diseases, X-LinkedGenetic Diseases, InbornHemorrhagic Disorders +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSpark Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSpark Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGenetic Diseases, X-LinkedGenetic Diseases, InbornHemorrhagic Disorders +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A